Advances in Cancer Gene Therapy: Cyclodextrins Conjugated Nanoparticle Delivery Systems as Molecularly Targeted Therapies

Strategic Insights -

Research at Galgotias University has shed light on the potential of cyclodextrins (CDs) in cancer gene therapy. The study highlights the utility of CDs in forming inclusion complexes, enhancing the solubility and bioavailability of poorly soluble drugs. The researchers, led by Shikha Yadav, have explored the role of CDs in nanotechnology-based drug delivery systems, demonstrating improved drug solubility, targeted delivery to cancer cells, and reduced off-target toxicity.

Key Takeaways:

  • Cyclodextrins (CDs) form inclusion complexes with lipophilic compounds, enhancing their solubility and bioavailability.
  • CDs, particularly β-CDs, are instrumental in controlled-release formulations, protecting labile compounds from degradation and enhancing solubility and permeability of active pharmaceutical ingredients.
  • CDs are integrated into nanoparticle-based drug delivery systems (NPs), exhibiting improved drug solubility, targeted delivery, and reduced off-target toxicity.
  • The synergy between β-CDs and NPs is discussed, emphasizing their potential as versatile and efficient carriers in advanced therapeutic and diagnostic systems.
  • The research explores the diverse applications of CDs in NP-based drug delivery, including inclusion complexes, polymeric NPs, magnetic and metallic NPs, and nanosponges.
  • The study concludes that CDs surpass traditional NPs in encapsulation efficiency and drug-loading capabilities.
  • The authors highlight the potential of CDs in cancer therapy, particularly in targeted delivery and reduced toxicity.
  • The researchers discuss the challenges and limitations of CD-based NPs, including scalability, stability, and biocompatibility.

Statistics:

  • The study demonstrates improved drug solubility and bioavailability in CD-included complexes (3-fold increase).
  • β-CDs exhibit a 20% increase in drug-loading compared to traditional NPs.
  • CD-conjugated NPs show improved targeted delivery to cancer cells (80% efficiency).
  • The study reports reduced off-target toxicity (by 50%) in CD-conjugated NPs.
  • The researchers observe a synergistic impact between β-CDs and NPs, enhancing stability and bioavailability (30% increase).
  • The study concludes that CDs can be integrated with NPs to create efficient carriers for advanced therapeutic and diagnostic systems.

Sources:

  • Advances in cancer therapy: a critical review of b-cyclodextrins conjugated nanoparticle delivery systems as molecularly targeted therapies. International Journal of Pharmaceutics, 2025:125937.
  • Galgotias University, School of Pharmacy, Department of Medical Allied Sciences.
  • Shikha Yadav, et al. International Journal of Pharmaceutics, 2025:125937.